HLA-A and acute myeloid leukemia: In humanized mouse models, adoptive T-cell transfer utilizing T cells transduced with a TCR recognizing an HLA-A*02-restricted hTERT-derived peptide were able to control human B-ALL, CLL, as well as AML progression in vivo, supporting the feasibility of hTERT-directed adoptive immunotherapy [126,127].